The active enantiomer of (RS)-atenolol (Cat. No. 0387), a cardioselective β-adrenergic blocker.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 25 mM in water|
Preparing Stock Solutions
The following data is based on the product molecular weight 266.34. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.75 mL||18.77 mL||37.55 mL|
|5 mM||0.75 mL||3.75 mL||7.51 mL|
|10 mM||0.38 mL||1.88 mL||3.75 mL|
|50 mM||0.08 mL||0.38 mL||0.75 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Stoschitzky et al (1993) Stereoselective features of (R)- and (S)-atenolol: clinical pharmacological, pharmacokinetic, and radioligand binding studies. Chirality 5 15 PMID: 8383518
If you know of a relevant reference for (S)-(-)-Atenolol, please let us know.
View Related Products by Product Action
Keywords: (S)-(-)-Atenolol, supplier, β1-Adrenergic, α1-Adrenergic, beta1-Adrenergic, b1-adrenergic, Receptors, β1-adrenoceptors, α1-adrenoceptor, beta1-adrenoceptors, b1-adrenoceptors, antagonists, Atenolol, S-Atenolol, Adrenergic, Beta-1, Receptors, Tocris Bioscience
Citations for (S)-(-)-Atenolol
Citations are publications that use Tocris products.
Currently there are no citations for (S)-(-)-Atenolol. Do you know of a great paper that uses (S)-(-)-Atenolol from Tocris? If so please let us know.
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.